Background & Aims: The prevalence of non-alcoholic fatty liver disease (NAFLD)
| INTRODUC TI ON
Non-alcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis in the absence of excessive alcohol use, and is emerging as the most common cause of chronic liver disease as a result of the global obesity epidemic. The spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis. 1 NAFLD is the hepatic manifestation of the metabolic syndrome (MetS) and coincides with an increased risk for development of type 2 diabetes mellitus (T2D). 1, 2 NAFLD coincides with plasma lipoprotein abnormalities, including elevations in apolipoprotein (Apo)B-containing lipoproteins, an increase in the ratio of ApoB to ApoA-I, decreased levels of high-density lipoprotein (HDL) cholesterol and increased levels of low-density lipoprotein (LDL) cholesterol. [3] [4] [5] Enhanced delivery of adipose tissue-derived fatty acids to the liver provides a central mechanism responsible for hepatic fat accumulation. In turn, increased liver fat content is regarded as the driving force of enhanced production of very low-density lipoproteins (VLDL) by the liver, resulting in an increased plasma concentration of large VLDL particles and consequently in higher triglycerides. 6, 7 Such plasma lipoprotein abnormalities predispose to atherosclerotic cardiovascular disease (CVD) 8, 9 with increased intima-media thickness and carotid plaques indicating higher risk of atherosclerotic CVD in NAFLD. 10 Although most patients with NAFLD are not at risk of dying from liver disease, they have increased risk of early morbidity and mortality because of CVD, which is the main cause of death in NAFLD. 1, 9 Furthermore, cardiovascular and all-cause morbidity and mortality increases exponentially with increasing fibrosis stage in NAFLD. 11, 12 Consequently, prevention and treatment of dyslipidaemia are especially important in subjects with NAFLD. The main therapeutic aim in the treatment of dyslipidaemias is LDL cholesterol-lowering treatment with 3-hydroxy 3-methylglutaryl-coenzyme A reductase inhibitors (statins). 13 However, restraint has been shown in the prescription of statins because of concerns about increased risk of hepatotoxicity. 14, 15 Nevertheless, statin treatment appears to be safe in NAFLD patients with elevated liver enzymes. [16] [17] [18] [19] In addition, experimental animal models with chronic liver injury have shown that statins have an anti-inflammatory and anti-fibrotic effect and decrease complications in NAFLD. [20] [21] [22] [23] Also in humans, statin use may improve disease progression, reduce cardiovascular morbidity 14, 16, 17 and decrease complications of chronic liver disease. 24 There are only a few small studies, which assess the utilization of statin therapy in patients with NAFLD and dyslipidaemia. Three small studies described appropriate prescription of statin therapy in only 44%-71% of NAFLD patients with dyslipidaemias and these patients were less likely than patients without NAFLD to receive appropriate statin care. [25] [26] [27] Furthermore, NAFLD was an independent factor in the lack of statin prescription in subjects with indication for lipid-lowering treatment. 27 Given the pivotal role of lipoprotein abnormalities in the development of NAFLD and consequent CVD, with high morbidity and mortality, the importance of dyslipidaemia treatment in subjects with NAFLD is evident. Therefore, we sought to determine the cardiovascular risk as well as the proportion of subjects with indication for statin therapy in subjects with suspected NAFLD in a large population-based cohort study.
| MATERIAL S AND ME THODS

| Study population
The study is a cross-sectional analysis of the population-based
Lifelines Cohort Study including a total of 167 729 persons from the northern part of the Netherlands. 28, 29 All participants provided written informed consent. The medical ethics committee of the University of Groningen, the Netherlands, approved the study conforming to the Declaration of Helsinki. 28, 29 Only subjects with data required to calculate Fatty Liver Index (FLI), 30 used as a proxy of NAFLD (described below), and /L) − 6.6 × albumin (g/dL). By applying a cut-off score >0.676, the presence of advanced fibrosis in NAFLD could be diagnosed with a sensitivity of 43%, specificity of 96% and positive predictive value of 82%. 32 The NFS is currently considered to be one of the best validated biomarkers to diagnose fibrosis among NAFLD subjects. 31, 33, 34 As alternative fibrosis marker, we used the LDL cholesterol (mmol/L), mean ± SD 3.1 ± 0.9 3.6 ± 0.9 <0.001
| Measurements and definitions
Triglycerides (mmol/L), median (IQR) 0.9 (0.7-1.1)
ApoB (g/L), mean ± SD 0.9 ± 0.1
ApoA-I (g/L), mean ± SD 1. . Abbreviations: ApoA-I, apolipoprotein A-I; ApoB, apolipoprotein B; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; FLI, Fatty Liver Index; GGT, gamma-glutamyltransferase; HbA1c, haemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; NFS, NAFLD fibrosis score.
TA B L E 2 (Continued)
TA B L E 2 Cardiovascular risk according to ESC/EAS dyslipidaemia guideline in 27 173 subjects with a Fatty Liver Index (FLI) < 60 and in 7067 subjects with a FLI ≥ 60 of advanced fibrosis in NAFLD with a sensitivity of 33%, specificity of 98% and positive predictive value of 80%. 33, 36 The diagnosis of T2D was confirmed when a subject had either self-reported on T2D, used glucose-lowering medication, had a fasting glucose ≥7.0 mmol/L or a HbA1c ≥47.5 mmol/mol (6.5% 
| Statistical analysis
Statistical analyses were performed with SPSS software (version 
| RE SULTS
From the Lifelines Cohort Study, 57 272 participants were older than 18 years and had available biomedical data. After applying exclusion criteria, the final study group consisted of 34 240 participants TA B L E 3 Intervention strategies in 27 173 subjects with a Fatty Liver Index (FLI) < 60 and in 7067 subjects with a FLI ≥ 60 as function of total cardiovascular risk and low-density lipoprotein cholesterol level ) × 100.
( Figure 1 ). Our study group was predominantly female (62.9%) with a mean age of 43 years.
Suspected NAFLD, defined as FLI ≥ 60, was present in 7067 (20.6%) subjects. Table 1 shows the clinical and laboratory characteristics in subjects with and without suspected NAFLD. Subjects with a FLI ≥ 60 were more likely to be classified with T2D, MetS, history of CVD and impaired renal function (all P < 0.001). As expected, the proportion of subjects with a NFS > 0.676, as proxy of advanced fibrosis, was also higher in subjects with suspected NAFLD (1.0% vs 0.3%, P < 0.001). Characteristics from 869 excluded subjects using statins are shown in Table S1 .
Estimated 10-year predicted cardiovascular risk was higher in subjects with a FLI ≥ 60 compared with subjects with a FLI < 60 ( vs 15.6%, P < 0.001). The proportion of subjects with a FLI ≥ 60 in need for statin therapy increased with higher LDL cholesterol levels and CVD risk prediction category as can be seen in Table 3 .
In subjects with suspected NAFLD and a NFS > 0.676 vs subjects with suspected NAFLD and a NFS ≤ 0.676, essentially similar differences in CVD risk and LDL cholesterol treatment intervention strategies were found (Table 4) . Estimated 10-year predicted total very high cardiovascular risk was approximately four times higher in subjects with a NFS > 0.676 compared to subjects with a NFS ≤ 0.676 (63.4% vs 13.4%, P < 0.001). Consequently, subjects with a NFS > 0.676 had an approximately 2.5 times higher indication for statin therapy (73.2% vs 30.6%, P < 0.001) and proportion of subjects with a NFS > 0.676 in need for statin therapy increased with higher LDL cholesterol levels and CVD risk prediction category (Table 5 ). In alternative analyses using a FIB-4 score ≥ 2.67 instead of a NFS > 0.676, essentially similar results were found (Table S2) .
Multivariable logistic regression analyses were subsequently performed in order to establish the extent to which statin therapy was independently associated with a FLI ≥ 60 (Table 6 , Figure 2A ).
After adjustment for age, sex, current smoking, presence of MetS and impaired renal function, indication for statin treatment was TA B L E 4 Cardiovascular risk according to ESC/EAS dyslipidaemia guideline in 6969 subjects with suspected NAFLD and a NAFLD fibrosis score (NFS) ≤ 0.676 and in 71 subjects with suspected NAFLD and a NFS > 0.676 positively associated with a FLI ≥ 60 ( The AUCs of the multivariable models (Table 6) 
| D ISCUSS I ON
In this cross-sectional analysis in a large population-based cohort study, we demonstrated that statin-naive subjects with suspected NAFLD, and suspected advanced fibrosis, have a significantly increased cardiovascular risk, and consequently a higher indication for statin therapy. Furthermore, in multivariable regression analyses, indication for statin therapy was independently associated with an elevated FLI as well as NFS. In this study, we have used the FLI and NFS in line with recommendations of international guidelines which advocate to use biomarker-derived algorithms in order to categorize subjects with probable NAFLD and fibrosis in large-scale studies. 31 Taken together, the present study demonstrates that an elevated FLI and NFS are independently associated with a higher need for statin therapy. We advocate that care for this high-risk group of subjects should be improved.
Statins have a pivotal role in primary and secondary prevention of cardiovascular diseases by decreasing the synthesis of cholesterol in the liver by inhibition of the mevalonate pathway through a competitive inhibitory effect on 3-hydroxy-3-methylglutaryl CoA reductase, which results in lowering of LDL, VLDL and consequently in lower triglycerides. 38 Also, statins have an effect on inhibition of inflammatory pathways, reduction of endothelial dysfunction, antioxidative effects, increased bioavailability of nitric oxide and stabilization of atherosclerotic plaques, all resulting in significant reduction of cardiovascular morbidity and mortality. 13, 38 In NAFLD, cardiovascular events are the main cause of mortality, probably driven by increased prevalence of T2D, MetS and plasma lipoprotein abnormalities that predispose to atherosclerotic cardiovascular disease. 1 Accumulating evidence demonstrates that statin therapy in NAFLD is safe and not to an important extent associated with hepatotoxicity. [16] [17] [18] [19] Severe liver injury caused by statins is rare, and in NAFLD, statin therapy should in fact be encouraged since the risk of cardiovascular mortality is much higher than its potential side effects. 19, 31 However, statin therapy may lead to a slightly increased TA B L E 5 Intervention strategies in 6969 subjects with suspected NAFLD and a NAFLD fibrosis score (NFS) ≤ 0.676 and in 71 subjects with suspected NAFLD and a NFS > 0.676 as function of total cardiovascular risk and low-density lipoprotein cholesterol level risk of development of T2D, but this seems largely outweighed by the cardiovascular benefit. 39 In the last decade, accumulating evidence has become available that statin therapy may even have beneficial effects in NAFLD. In human studies, the administration of statins resulted in an improvement of ultrasonographic amount of hepatic steatosis. 40 Studies with biopsy-proven NAFLD and NASH showed mainly positive results of statin use: reduced formation of steatosis and fibrosis and a protective effect on liver damage in NASH. [41] [42] [43] In two large clinical trials, normalization of transaminase levels was found in patients treated with simvastatin or atorvastatin, with concomitant increased cardiovascular benefit in patients with mildly-to-moderately elevated baseline transaminases. 17, 44 Furthermore, a meta-analysis demonstrated that statin use is probably associated with lower risk of hepatic decompensation, reduction of portal hypertension and lowering of mortality in patients with chronic liver disease. 24 Previous studies that have investigated the indication for statin therapy in subjects with NAFLD are scarce. To date, our study is the only study assessing the indication for statin therapy in statin-naive subjects with suspected NAFLD from the general population. Del
Ben et al assessed cardiovascular risk and statin therapy indication in 605 subjects referred to the outpatient clinic for screening of suspected metabolic diseases. They described that 44% of NAFLD patients with indication for statin use were on therapy. 27 However, this study was performed in a selected high metabolic risk group. Blais et al conducted a medical record review of 255 dyslipidaemic NAFLD patients from a Veteran database, where only 59.6% received appropriate statin therapy. Interestingly, from this group, 38.1% received TA B L E 6 Multivariable binary logistic regression analyses demonstrating the positive association of indication for statin therapy with an elevated Fatty Liver Index (FLI) in 34 240 subjects and the association of indication for statin therapy with the NAFLD fibrosis score (NFS) in subjects with suspected NAFLD in 7067 subjects . Abbreviations: CI, confidence interval; FLI, Fatty Liver Index; HDL, high-density lipoproteins; MetS, metabolic syndrome; NFS, NAFLD fibrosis score; OR, odds ratio. Model 1: adjusted for age, sex, Fatty Liver Index, current smoking, metabolic syndrome and impaired renal function. Model 2: adjusted for age, sex, Fatty Liver Index, current smoking, individual metabolic syndrome criteria (abdominal obesity, hyperglycaemia, hypertension, elevated triglycerides and low HDL cholesterol) and impaired renal function. Model 3: adjusted for age, sex, NAFLD fibrosis sore, current smoking, metabolic syndrome and impaired renal function. Model 4: adjusted for age, sex, NAFLD fibrosis sore, current smoking, individual metabolic syndrome criteria (abdominal obesity, hyperglycaemia, hypertension, elevated triglycerides and low HDL cholesterol) and impaired renal function.
statin dose reduction or even discontinuation at time of NAFLD detection and the most important determinant for inappropriate statin use was recognition of NAFLD, 25 both probably because of fear for hepatotoxicity. In a correspondence letter, Taii et al described in 9960 patients with NAFLD and high LDL cholesterol that 71% of patients received statin therapy, but additional cardiovascular or metabolic information from these subjects was unfortunately not presented. 26 Our study has several strengths. Considering a sample size of over 34 000 individuals, this is the largest study to date reporting on the indication for statin therapy in subjects with NAFLD and fibrosis.
Furthermore, this enabled careful calculations on effect sizes, sufficiently powered subgroup analysis and multivariable models presenting excellent predictive performance. Additionally, the Lifelines Cohort Study population has been well characterized, with extensive validated questionnaires and standardized measurements and all laboratory measurements were performed in a single reference laboratory. 28, 29 From that, a complete cardiovascular risk profile of all subjects could be realized.
Several other methodological aspects and limitations also need to be addressed. First, its cross-sectional design does not allow cause-effect relationships to be established with certainty. Second, studies. Given these considerations, serum biomarkers are the preferred diagnostic tool for large-scale screening studies and the FLI and NFS seem to perform best in European subjects, which is probably related to the ethnical difference in fat distribution. 31, 32, 34 In conclusion, because of increased cardiovascular risk in NAFLD, a substantial proportion of subjects with suspected NAFLD and fibrosis could benefit from lipid-lowering treatment and statin therapy should thus be encouraged.
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